The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 4 of 5 of this archive, newest first.
A proper account of an operation that existed, and of what closing it cost.
The document is four pages. Three of them are about dates.
Follow the resin, not the catalogue.
The header identifies the batch, the table records the tests, and the footer says who is answerable. Two of the three are usually incomplete.
Two withdrawal-design trials tell us what happens when treatment stops. Neither tells us what the lowest effective maintenance dose is.
The route did not close because of a rule about peptides.
Reported from the sessions, and from the two hours afterwards.
Efficacy was never the question in this appraisal. Duration of treatment was.
Follow the resin, not the catalogue.
The assay is not the problem. The interpretation of a lagging integral as a current measurement is the problem.
A brief and unromantic tour of the interface between a liquid sample and a vacuum.
The route did not close because of a rule about peptides.
Reported from the sessions, and from the two hours afterwards.
A reminder that a purity figure is the output of a method, and that methods differ.
Follow the resin, not the catalogue.
These agents produce no dependence and no withdrawal syndrome. What a taper would be for is therefore a real question rather than an obvious one.
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
Chain of custody, in a regulated setting, begins at sampling. Here it begins when the package arrives.
Reported from the analysis, not from a warning notice.
Reported from the analysis, not from a warning notice.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
Reported from the analysis, not from a warning notice.
Reported from the sessions, and from the two hours afterwards.
The route did not close because of a rule about peptides.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
Parts per million sound impressive until they are converted into daltons at the molecular weight of the thing being measured.
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
A proper account of an operation that existed, and of what closing it cost.
The document is four pages. Three of them are about dates.
Follow the resin, not the catalogue.
Nothing on this page is difficult. It is simply unfamiliar, and unfamiliarity is what makes a weak certificate look like a strong one.
A unit is a volume. A dose is a mass. The bridge between them is concentration, and concentration is a number somebody has to calculate.
Efficacy was never the question in this appraisal. Duration of treatment was.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
What would make a difference is not a regulator. It is three lines on a certificate, all of which are already known to whoever wrote it.
The supplier confirmed the determination and supplied the method behind its own figure inside a week.